or
Bookmark and Share
Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
   
Document Number
US Patent 7129039
Issued Date
October 31, 2006
Link
Inventors
Map
Abstract
Novel genes expressed selectively by long-term dendritic cell (DC) lines (XS series) from murine epidermis which retain important features of resident epidermal Langerhans cells (LC) are provided. These genes encode distinct type II membrane-integrated polypeptides, each consisting of a cytoplasmic domain, a transmembrane domain, an extracellular connecting domain, and a C-terminal extracellular domain that exhibits significant homology to the carbohydrate recognition domains (CRD) of C-type lectins. Expression of both genes is highly restricted to cells of DC lineage (including epidermal LC). Thus, these genes encode new, DC-specific members of the C-type lectin family, now termed "DC-associated C-type lectin-1 and -2" (dectin-1 and dectin-2). Two isoforms of the dectin-1 molecule and five isoforms of the dectin-2 molecule have also been identified. The invention further provides His-tagged fusion proteins comprising 6.times. histidine and the extracellular domain of dectin-1 or dectin-2. Also provided are antibodies raised to synthetic peptides designed from the dectin-1 sequence or to the His-tagged fusion proteins described.
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
8
Comments:
no comments yet
Published
October 31, 2006
Application Number
10/201,060
Filed
July 23, 2002
US Classification
435/4   436/501
Int'l Classification
C12Q   1/00   (20060101)   G01N   33/53   (20060101)  
Attorney/Law Firm
Parent Case
This is a divisional of application Ser. No. 09/396,492 filed Sep. 14, 1999, itself a divisional of application Ser. No. 08/772,440 filed Dec. 20, 1996, now issued U.S. Pat. No. 6,046,158, the entire disclosure of which is incorporated herein by reference without disclaimer and to which benefit of priority is claimed. The government owns rights in the present invention pursuant to grant numbers R01AR35068 and R01AR41150 from the National Institutes of Health.
USPTO Field of Search
435/4   436/501  
Related Patents
Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us